The first patient has been dosed in MacroGenics' (NASDAQ:MGNX) Phase 2/3 MAHOGANY clinical trial of margetuximab, a Fc-optimized monoclonal antibody targeting HER2, in combination with a checkpoint inhibitor, with or without chemotherapy, as a potential first-line treatment for patients with HER2-positive gastric or gastroesophageal junction cancer.
The primary outcome measure for efficacy is objective response rate per Response Evaluation Criteria in Solid Tumors and overall survival.
The trial is planned to be conducted in collaboration with Zai Lab (NASDAQ:ZLAB), the company’s regional partner in Greater China.
https://seekingalpha.com/news/3509630-macrogenics-launches-mid-stage-mahogany-study-gastric-gastroesophageal-junction-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.